Abstract	O

Background	O
.	O

Interventions	O
mitigating	O
progression	O
to	O
mechanical	O
ventilation	O
in	O
COVID	O
19	O
would	O
markedly	O
improve	O
outcome	O
and	O
reduce	O
healthcare	O
utilization	O
.	O

We	O
hypothesized	O
that	O
immunomodulation	O
with	O
IVIG	O
would	O
improve	O
oxygenation	O
and	O
reduce	O
length	O
of	O
hospital	O
stay	O
and	O
progression	O
to	O
mechanical	O
ventilation	O
in	O
COVID	O
19	O
pneumonia	O
.	O

Methods	O
.	O

Patients	O
with	O
COVID	O
19	O
were	O
randomized	O
1	O
:	O
1	O
to	O
prospectively	O
receive	O
standard	O
of	O
care	O
(	O
SOC	O
)	O
plus	O
IVIG	O
0	O
.	O
5	O
g	O
/	O
kg	O
/	O
day	O
x	O
3	O
days	O
with	O
methylprednisolone	O
40	O
mg	O
30	O
minutes	O
before	O
infusion	O
versus	O
SOC	O
alone	O
.	O

Clinical	O
data	O
extraction	O
and	O
analysis	O
.	O

Relevant	O
clinical	O
and	O
laboratory	O
information	O
was	O
captured	O
to	O
allow	O
for	O
group	O
comparisons	O
,	O
including	O
the	O
calculation	O
of	O
Charlson	O
comorbidity	O
index	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
mdcalc	O
.	O
com	O
/	O
charlson	O
comorbidity	O
index	O
cci	O
)	O
and	O
APACHE	O
II	O
acute	O
illness	O
severity	O
score	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
mdcalc	O
.	O
com	O
/	O
apache	O
ii	O
score	O
#	O
next	O
steps	O
)	O
.	O

The	O
alveolar	O
arterial	O
(	O
A	O
a	O
)	O
gradient	O
was	O
calculated	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
mdcalc	O
.	O
com	O
/	O
a	O
a	O
o2	O
gradient	O
)	O
for	O
each	O
subject	O
at	O
the	O
time	O
of	O
enrollment	O
based	O
on	O
arterial	O
blood	O
gases	O
when	O
available	O
or	O
based	O
on	O
PaO2	O
extrapolated	O
SpO2	O
and	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
FiO2	O
)	O
.	O

Interleukin	O
6	O
was	O
measured	O
from	O
blood	O
24	O
48	O
hours	O
after	O
enrollment	O
(	O
https	O
:	O
/	O
/	O
ltd	O
.	O
aruplab	O
.	O
com	O
/	O
Tests	O
/	O
Pub	O
/	O
0051537	O
)	O
.	O

Clinical	O
outcomes	O
.	O

The	O
two	O
patient	O
groups	O
were	O
well	O
matched	O
with	O
respect	O
to	O
their	O

Charlson	O
comorbidity	O
index	O
and	O
severity	O
of	O
illness	O
APACHE	O
2	O
scores	O
(	O
Figure	O
2	O
)	O
.	O

Median	O

Charlson	O
index	O
was	O
2	O
for	O
both	O
groups	O
.	O

Median	O
APACHE	O
2	O
score	O
was	O
7	O
for	O
SOC	O
and	O
7	O
.	O
5	O
the	O
IVIG	O
study	O
group	O
.	O

Figure	O
2	O
demonstrates	O
the	O
subjects	O
in	O
the	O
control	O
SOC	O
and	O
treatment	O
IVIG	O
group	O
that	O
developed	O
a	O
need	O
for	O
mechanical	B-OtherOutcome
ventilation	I-OtherOutcome
after	O
study	O
enrollment	O
,	O
denoted	O
as	O
the	O
red	O
data	O
points	O
.	O

An	O
overall	O
trend	O
is	O
for	O
receipt	O
of	O
mechanical	O
ventilation	O
in	O
the	O
IVIG	O
group	O
in	O
the	O
2	O
patients	O
with	O
highest	O
comorbidity	O
and	O
illness	O
severity	O
scores	O
,	O
whereas	O
in	O
the	O
SOC	O
group	O
mechanical	O
ventilation	O
requirement	O
developed	O
across	O
the	O
entire	O
spectrum	O
of	O
scores	O
.	O

Among	O
the	O
entire	O
enrolled	O
and	O
evaluated	O
subjects	O
in	O
each	O
arm	O
,	O
2	O
patients	O
in	O
the	O
IVIG	O
arm	O
and	O
7	O
patients	O
in	O
the	O
control	O
SOC	O
arm	O
developed	O
a	O
need	O
for	O
mechanical	O
ventilation	O
.	O

Among	O
these	O
7	O
SOC	O
patients	O
,	O
6	O
received	O
ventilation	O
and	O
1	O
was	O
made	O
a	O
‘	O
do	O
not	O
intubate	O
’	O
and	O
the	O
patient	O
expired	O
within	O
24	O
hours	O
.	O

The	O
difference	O
in	O
receipt	O
of	O
mechanical	O
ventilation	O
was	O
not	O
statistically	O
significant	O
between	O
the	O
two	O
groups	O
(	O
p	O
=	O
0	O
.	O
12	O
,	O
Fisher	O
exact	O
test	O
)	O
.	O

Among	O
subjects	O
whose	O
respiratory	O
failure	O
progressed	O
to	O
the	O
need	O
for	O
mechanical	O
ventilation	O
,	O
1	O
of	O
2	O
IVIG	O
subjects	O
and	O
2	O
of	O
3	O
control	O
subjects	O
also	O
received	O
concomitant	O
convalescent	O
plasma	O
.	O

Concomitant	O
glucocorticoid	O
therapy	O
was	O
given	O
to	O
5	O
of	O
the	O
7	O
control	O
subjects	O
who	O
progressed	O
to	O
mechanical	O
ventilation	O
.	O

The	O
use	O
of	O
remdesivir	O
was	O
.	O
CC	O
-	O
BY	O
-	O
NC	O
-	O
ND	O
4	O
.	O
0	O
International	O
licenseIt	O
is	O
made	O
available	O
under	O
a	O
is	O
the	O
author	O
/	O
funder	O
,	O
who	O
has	O
granted	O
medRxiv	O
a	O
license	O
to	O
display	O
the	O
preprint	O
in	O
perpetuity	O
.	O
(	O
which	O
was	O
not	O
certified	O
by	O
peer	O
review	O
)	O

The	O
copyright	O
holder	O
for	O
this	O
preprintthis	O
version	O
posted	O
July	O
25	O
,	O
2020	O
.	O
;	O
https	O
:	O
/	O
/	O
doi	O
.	O
org	O
/	O
10	O
.	O
1101	O
/	O
2020	O
.	O
07	O
.	O
20	O
.	O
20157891doi	O
:	O
medRxiv	O
preprint	O
11	O
dependent	O
on	O
its	O
availability	O
after	O
May	O
13	O
,	O
2020	O
and	O
therefore	O
all	O
patients	O
admitted	O
after	O
that	O
date	O
whose	O
respiratory	O
failure	O
progressed	O
to	O
needing	O
mechanical	O
ventilation	O
received	O
it	O
.	O

This	O
resulted	O
in	O
1	O
of	O
2	O
IVIG	O
patients	O
and	O
3	O
of	O
7	O
SOC	O
subjects	O
that	O
required	O
ventilation	O
receiving	O
remdesivir	O
.	O

Alveolar	B-OtherOutcome
arterial	I-OtherOutcome
(	I-OtherOutcome
A	I-OtherOutcome
a	I-OtherOutcome
)	I-OtherOutcome
gradients	I-OtherOutcome
were	O
calculated	O
directly	O
from	O
arterial	O
blood	O
gas	O
or	O
estimated	O
based	O
on	O
PaO2	O
and	O
FiO2	O
measurement	O
.	O

Based	O
on	O
an	O
increase	O
in	O
APACHE	O
II	O
severity	O
of	O
illness	O
scoring	O
associated	O
with	O
achieving	O
and	O
A	O
a	O
gradient	O
of	O
>	O
200	O
mm	O
Hg	O
(	O
+	O
2	O
points	O
)	O
,	O
subjects	O
were	O
stratified	O
into	O
those	O
with	O
A	O
a	O
gradient	O
<	O
200	O
mm	O
Hg	O
or	O
>	O
200	O
mm	O
Hg	O
,	O
corresponding	O
to	O
a	O
PaO2	O
/	O
FiO2	O
of	O
<	O
140	O
,	O
or	O
the	O
approximate	O
requirement	O
of	O
6	O
liters	O
O2	O
by	O
nasal	O
cannula	O
for	O
a	O
PaO2	O
of	O
<	O
92	O
%	O
.	O

As	O
shown	O
in	O
Figure	O
3A	O
,	O
none	O
of	O
the	O
7	O
subjects	O
(	O
5	O
SOC	O
,	O
2	O
IVIG	O
)	O
with	O
A	O
a	O
gradient	O
<	O
200	O
mm	O
Hg	O
progressed	O
to	O
mechanical	O
ventilation	O
,	O
but	O
for	O
subjects	O
with	O
A	O
a	O
gradient	O
of	O
>	O
200	O
mm	O
Hg	O
at	O
enrollment	O
,	O
the	O
progression	O
to	O
mechanical	O
ventilation	O
was	O
7	O
/	O
12	O
(	O
58	O
%	O
)	O
in	O
the	O
SOC	O
control	O
arm	O
vs	O
2	O
/	O
14	O
(	O
14	O
%	O
)	O
in	O
the	O
IVIG	O
,	O
a	O
difference	O
that	O
was	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
038	O
,	O
Fisher	O
Exact	O
test	O
)	O
.	O

Evaluation	O
of	O
overall	O
hospital	O
course	O
,	O
including	O
length	O
of	O
hospital	O
stay	O
and	O
length	O
of	O
ICU	O
stay	O
also	O
was	O
highly	O
dependent	O
on	O
A	O
a	O
gradient	O
stratification	O
.	O

Among	O
the	O
7	O
patients	O
with	O
A	O
a	O
gradient	O
<	O
200	O
mm	O
Hg	O
,	O
no	O
patient	O
required	O
ICU	O
stay	O
during	O
their	O
illness	O
and	O
length	O
of	O
hospital	O
stay	O
were	O
3	O
8	O
days	O
.	O

However	O
,	O
for	O
the	O
subjects	O
with	O
A	O
a	O
gradient	O
>	O
200	O
at	O
enrollment	O
,	O
median	B-OtherOutcome
length	I-OtherOutcome
of	I-OtherOutcome
hospital	I-OtherOutcome
stay	I-OtherOutcome
was	O
19	O
(	O
range	O
4	O
30	O
)	O
and	O
11	O
(	O
range	O
5	O
22	O
)	O
days	O
for	O
SOC	O
and	O
IVIG	O
groups	O
,	O
respectively	O
(	O
p	O
=	O
0	O
.	O
013	O
,	O
Mann	O
Whitney	O
U	O
test	O
,	O
Figure	O
3B	O
)	O
.	O

Median	B-OtherOutcome
ICU	I-OtherOutcome
stay	I-OtherOutcome
were	O
12	O
.	O
5	O
days	O
(	O
range	O
1	O
29	O
)	O
and	O
2	O
.	O
5	O
days	O
(	O
range	O
0	O
16	O
)	O
for	O
SOC	O
and	O
IVIG	O
,	O
respectively	O
(	O
p	O
=	O
0	O
.	O
006	O
,	O
Mann	O
Whitney	O
U	O
test	O
,	O
Figure	O
3C	O
)	O
.	O

Total	O
ventilator	O
patient	O
.	O
CC	O
-	O
BY	O
-	O
NC	O
-	O
ND	O
4	O
.	O
0	O
International	O
licenseIt	O
is	O
made	O
available	O
under	O
a	O
is	O
the	O
author	O
/	O
funder	O
,	O
who	O
has	O
granted	O
medRxiv	O
a	O
license	O
to	O
display	O
the	O
preprint	O
in	O
perpetuity	O
.	O
(	O
which	O
was	O
not	O
certified	O
by	O
peer	O
review	O
)	O

The	O
copyright	O
holder	O
for	O
this	O
preprintthis	O
version	O
posted	O
July	O
25	O
,	O
2020	O
.	O
;	O
https	O
:	O
/	O
/	O
doi	O
.	O
org	O
/	O
10	O
.	O
1101	O
/	O
2020	O
.	O
07	O
.	O
20	O
.	O
20157891doi	O
:	O
medRxiv	O
preprint	O
12	O
days	O
were	O
98	O
days	O
for	O
SOC	O
(	O
5	O
.	O
8	O
days	O
/	O
patient	O
enrolled	O
)	O
and	O
23	O
days	O
for	O
the	O
IVIG	O
group	O
(	O
1	O
.	O
4	O
days	O
/	O
patient	O
enrolled	O
)	O
.	O

The	O
supplementary	O
Figure	O
shows	O
schematically	O
the	O
hospital	O
stays	O
from	O
the	O
time	O
of	O
admission	O
of	O
the	O
33	O
enrolled	O
patients	O
with	O
respect	O
to	O
medical	O
floor	O
and	O
ICU	O
stays	O
with	O
and	O
without	O
mechanical	O
ventilation	O
.	O

Improvement	B-OtherOutcome
in	I-OtherOutcome
oxygenation	I-OtherOutcome
was	O
evaluated	O
by	O
examining	O
the	O
PaO2	O
/	O
FiO2	O
ratio	O
at	O
the	O
day	O
of	O
enrollment	O
and	O
7	O
days	O
after	O
enrollment	O
in	O
individual	O
subjects	O
for	O
SOC	O
(	O
Figure	O
4A	O
)	O
and	O
IVIG	O
(	O
Figure	O
4B	O
)	O
.	O

Differences	O
in	O
day	O
7	O
PaO2	O
/	O
FiO2	O
minus	O
enrollment	O
PaO2	O
/	O
FiO2	O
are	O
shown	O
in	O
Figure	O
4C	O
for	O
both	O
groups	O
,	O
with	O
negative	O
numbers	O
representing	O
worsening	O
in	O
oxygenation	O
.	O

Among	O
the	O
entire	O
subject	O
population	O
,	O
median	O
improvement	O
PaO2	O
/	O
FiO2	O
for	O
IVIG	O
was	O
+	O
153	O
(	O
range	O
+	O
35	O
to	O
+	O
330	O
)	O
and	O
was	O
better	O
than	O
SOC	O
+	O
90	O
(	O
range	O
115	O
to	O

+	O
280	O
)	O
,	O
but	O
did	O
not	O
reach	O
statistical	O
significance	O
(	O
p	O
=	O
0	O
·	O
057	O
,	O
Mann	O
Whitney	O
U	O
test	O
)	O
.	O

However	O
,	O
when	O
refocusing	O
on	O
the	O
higher	O
risk	O
patients	O
with	O
A	O
a	O
gradient	O
>	O
200	O
at	O
enrollment	O
,	O
median	O
improvement	O
of	O
PaO2	O
/	O
FiO2	O
for	O
IVIG	O
was	O
significantly	O
greater	O
than	O
SOC	O
,	O
with	O
median	O
(	O
range	O
)	O
of	O
+	O
131	O
(	O
+	O
35	O
to	O
+	O
330	O
)	O
versus	O
+	O
44	O
·	O
5	O
(	O
115	O
to	O
+	O
157	O
)	O
(	O
p	O
=	O
0	O
·	O
01	O
,	O

Mann	O
Whitney	O
U	O
test	O
)	O
.	O

Figure	O
4C	O
denotes	O
subjects	O
in	O
the	O
SOC	O
group	O
who	O
did	O
not	O
receive	B-OtherOutcome
any	I-OtherOutcome
glucocorticoid	I-OtherOutcome
therapy	I-OtherOutcome
as	O
red	O
data	O
points	O
.	O

Seven	O
subjects	O
in	O
SOC	O
did	O
not	O
receive	O
glucocorticoids	O
,	O
4	O
of	O
whom	O
were	O
in	O
the	O
low	O
risk	O
group	O
with	O
A	O
a	O
gradient	O
<	O
200	O
.	O

Of	O
the	O
remaining	O
3	O
patients	O
,	O
2	O
progressed	O
to	O
requiring	O
mechanical	O
ventilation	O
,	O
one	O
of	O
which	O
was	O
made	O
do	O
not	O
intubate	O
and	O
died	O
.	O

PaO2	O
/	O
FiO2	O
changes	O
between	O
enrollment	O
and	O
day	O
7	O
of	O
the	O
10	O
SOC	O
patients	O
who	O
received	O
glucocorticoid	O
therapy	O
(	O
median	O
11	O
days	O
)	O
was	O
median	O
+	O
53	O
(	O
range	O
115	O
to	O

+	O
216	O
)	O
,	O
a	O
difference	O
that	O
remained	O
significantly	O
lower	O
than	O
the	O
IVIG	O
group	O
(	O
p	O
=	O
0	O
.	O
0057	O
,	O

Mann	O
Whiney	O
U	O
test	O
)	O
.	O

.	O
CC	O
-	O
BY	O
-	O
NC	O
-	O
ND	O
4	O
.	O
0	O
International	O
licenseIt	O
is	O
made	O
available	O
under	O
a	O
is	O
the	O
author	O
/	O
funder	O
,	O
who	O
has	O
granted	O
medRxiv	O
a	O
license	O
to	O
display	O
the	O
preprint	O
in	O
perpetuity	O
.	O
(	O
which	O
was	O
not	O
certified	O
by	O
peer	O
review	O
)	O

The	O
copyright	O
holder	O
for	O
this	O
preprintthis	O
version	O
posted	O
July	O
25	O
,	O
2020	O
.	O
;	O
https	O
:	O
/	O
/	O
doi	O
.	O
org	O
/	O
10	O
.	O
1101	O
/	O
2020	O
.	O
07	O
.	O
20	O
.	O
20157891doi	O
:	O
medRxiv	O
preprint	O

